Compare OGN & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGN | JANX |
|---|---|---|
| Founded | 1923 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 790.3M |
| IPO Year | 2020 | 2021 |
| Metric | OGN | JANX |
|---|---|---|
| Price | $6.41 | $13.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $11.75 | ★ $53.60 |
| AVG Volume (30 Days) | ★ 3.9M | 786.3K |
| Earning Date | 05-14-2026 | 06-01-2026 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $6,216,000,000.00 | $10,000,000.00 |
| Revenue This Year | $0.42 | N/A |
| Revenue Next Year | $1.67 | $209.90 |
| P/E Ratio | $8.98 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.18 | $12.12 |
| 52 Week High | $15.88 | $35.34 |
| Indicator | OGN | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 31.55 | 54.01 |
| Support Level | $6.34 | $13.80 |
| Resistance Level | $7.87 | $15.49 |
| Average True Range (ATR) | 0.30 | 0.51 |
| MACD | -0.09 | 0.13 |
| Stochastic Oscillator | 7.89 | 73.91 |
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.